Long-term use of inhaled glucocorticoids in patients with stable chronic obstructive pulmonary disease and risk of bone fractures: a narrative review of the literature

References

• Abdool-Gaffar MS, Ambaram A, Ainslie GM, et al. Guideline for the management of chronic obstructive pulmonary disease–2011 update. S Afr Med J. 2011;101(1 Pt 2):63–73.21526617
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report) [Internet]. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed 46, 2018.
   Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625–637. doi:10.1183/13993003.01170-201526797035
   PubMed Web of Science ®Google Scholar
• O‘Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J. 2008;15(Suppl A):1a–8a.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179–191. doi:10.7326/0003-4819-155-3-201108020-0000821810710
   PubMed Web of Science ®Google Scholar
• Chee C, Sellahewa L, Pappachan JM. Inhaled corticosteroids and bone health. Open Respir Med J. 2014;8:85–92. doi:10.2174/187430640140801008525674178
   PubMedGoogle Scholar
• Liu WT, Kuo HP, Liao TH, et al. Low bone mineral density in COPD patients with osteoporosis is related to low daily physical activity and high COPD assessment test scores. Int J Chron Obstruct Pulmon Dis. 2015;10:1737–1744.26366066
   PubMed Web of Science ®Google Scholar
• Sutter SA, Stein EM. The skeletal effects of inhaled glucocorticoids. Curr Osteoporos Rep. 2016;14(3):106–113. doi:10.1007/s11914-016-0308-127091558
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMc06319017314337
   PubMed Web of Science ®Google Scholar
• Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66(8):699–708. doi:10.1136/thx.2011.16002821602540
   PubMed Web of Science ®Google Scholar
• Weatherall M, James K, Clay J, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008;38(9):1451–1458. doi:10.1111/j.1365-2222.2008.03029.x18537983
   PubMed Web of Science ®Google Scholar
• Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;18(2):CD002991.
   Google Scholar
• Arai M, Nagasawa T, Koshihara Y, Yamamoto S, Togari A. Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta. 2003;1640(2–3):137–142. doi:10.1016/S0167-4889(03)00042-912729923
   PubMed Web of Science ®Google Scholar
• Bonnet N, Brunet-Imbault B, Arlettaz A, et al. Alteration of trabecular bone under chronic beta2 agonists treatment. Med Sci Sports Exerc. 2005;37(9):1493–1501. doi:10.1249/01.mss.0000177592.82507.9516177600
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Caffarelli C, Maggi S, et al. Effect of inhaled glucocorticoids and beta(2) agonists on vertebral fracture risk in COPD patients: the EOLO study. Calcif Tissue Int. 2010;87(2):137–143. doi:10.1007/s00223-010-9392-x20567964
   PubMed Web of Science ®Google Scholar
• Shi Y, Oury F, Yadav VK, et al. Signaling through the M(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell Metab. 2010;11(3):231–238. doi:10.1016/j.cmet.2010.01.00520197056
   PubMed Web of Science ®Google Scholar
• Ternes S, Trinkaus K, Bergen I, et al. Impact of acetylcholine and nicotine on human osteoclastogenesis in vitro. Int Immunopharmacol. 2015;29(1):215–221. doi:10.1016/j.intimp.2015.10.00826386154
   PubMed Web of Science ®Google Scholar
• Veldhuis-Vlug AG, Oei L, Souverein PC, et al. Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density. Osteoporos Int. 2015;26(7):2019–2027. doi:10.1007/s00198-015-3087-025910744
   PubMed Web of Science ®Google Scholar
• Veldhuis-Vlug AG, Tanck MW, Limonard EJ, et al. The effects of beta-2 adrenergic agonist and antagonist on human bone metabolism: a randomized controlled trial. Bone. 2015;71:196–200. doi:10.1016/j.bone.2014.10.02425451321
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–919. doi:10.1183/09031936.03.0002700314680078
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340(25):1948–1953. doi:10.1056/NEJM19990513340190910379018
   PubMed Web of Science ®Google Scholar
• Renkema TE, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest. 1996;109(5):1156–1162. doi:10.1378/chest.109.5.11568625660
   PubMed Web of Science ®Google Scholar
• Shaker SB, Dirksen A, Ulrik CS, et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. Copd. 2009;6(2):104–111. doi:10.1080/1541255090277259319378223
   PubMedGoogle Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81.12570112
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819–1823. doi:10.1016/S0140-6736(98)09449-510359405
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–1303. doi:10.1136/bmj.320.7245.129710807619
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456. doi:10.1016/S0140-6736(03)12459-212583942
   PubMed Web of Science ®Google Scholar
• Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009;151(8):517–527. doi:10.7326/0003-4819-151-8-200910200-0000419841453
   PubMed Web of Science ®Google Scholar
• Van Grunsven P, Schermer T, Akkermans R, et al. Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respir Med. 2003;97(12):1303–1312. doi:10.1016/j.rmed.2003.08.00114682412
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9:73. doi:10.1186/1465-9921-9-7319014549
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. Int J Chron Obstruct Pulmon Dis. 2012;7:43–55.22334768
   PubMed Web of Science ®Google Scholar
• Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:57–71. doi:10.2147/COPD.S2732022334769
   PubMed Web of Science ®Google Scholar
• Weir DC, Bale GA, Bright P, Sherwood Burge P. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin Exp Allergy. 1999;29(Suppl 2):125–128. doi:10.1046/j.1365-2222.1999.00021.x
   PubMed Web of Science ®Google Scholar
• Wise R, Connett J, Weinmann G, Scanlon P, Skeans M; Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343(26):1902–1909. doi:10.1056/NEJM20001228343260111136260
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-127203508
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Calverley PMA, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009;136(6):1456–1465. doi:10.1378/chest.08-301619581353
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index. J Bone Miner Res. 2000;15(2):322–331. doi:10.1359/jbmr.2000.15.9.179810703935
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2009;41(6):631–638. doi:10.1165/rcmb.2009-0220TR19717810
   PubMed Web of Science ®Google Scholar
• Debigare R, Marquis K, Cote CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest. 2003;124(1):83–89. doi:10.1378/chest.124.1.8312853506
   PubMed Web of Science ®Google Scholar
• Balasubramanian V, Naing S. Hypogonadism in chronic obstructive pulmonary disease: incidence and effects. Curr Opin Pulm Med. 2012;18(2):112–117. doi:10.1097/MCP.0b013e32834feb3722234275
   PubMed Web of Science ®Google Scholar
• Kamischke A, Kemper DE, Castel MA, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J. 1998;11(1):41–45. doi:10.1183/09031936.98.110100419543268
   PubMed Web of Science ®Google Scholar
• Stanojkovic I, Kotur-Stevuljevic J, Spasic S, et al. Relationship between bone resorption, oxidative stress and inflammation in severe COPD exacerbation. Clin Biochem. 2013;46(16–17):1678–1682. doi:10.1016/j.clinbiochem.2013.04.01123954853
   PubMed Web of Science ®Google Scholar
• Georgiou KR, Hui SK, Xian CJ. Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. Am J Stem Cells. 2012;1(3):205–224.23671809
   PubMedGoogle Scholar
• Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011;286(52):44326–44335. doi:10.1074/jbc.M111.28348122030390
   PubMed Web of Science ®Google Scholar
• Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest. 2006;116(8):2152–2160. doi:10.1172/JCI2808416878176
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001;16(3):581–588. doi:10.1359/jbmr.2001.16.3.58111277277
   PubMed Web of Science ®Google Scholar
• de Vries F, Pouwels S, Lammers JW, et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med. 2007;261(2):170–177. doi:10.1111/j.1365-2796.2006.01754.x17241182
   PubMed Web of Science ®Google Scholar
• Cawthon PM. Gender differences in osteoporosis and fractures. Clin Orthop Relat Res. 2011;469(7):1900–1905. doi:10.1007/s11999-011-1780-721264553
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis Int. 2002;13(10):777–787. doi:10.1007/s001980200108
   PubMed Web of Science ®Google Scholar
• van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224–3229. doi:10.1002/art.1128314613287
   PubMed Web of Science ®Google Scholar
• Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int. 2003;14(Suppl 3):S13–S18. doi:10.1007/s00198-002-1345-412730800
   PubMed Web of Science ®Google Scholar
• Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(12):1286–1293. doi:10.1164/rccm.200406-754OC15374843
   PubMed Web of Science ®Google Scholar
• Kiel DP, Zhang Y, Hannan MT, Anderson JJ, Baron JA, Felson DT. The effect of smoking at different life stages on bone mineral density in elderly men and women. Osteoporos Int. 1996;6(3):240–248. doi:10.1007/BF16227418783299
   PubMed Web of Science ®Google Scholar
• Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ. 1997;315(7112):841–846. doi:10.1136/bmj.315.7112.8419353503
   PubMed Web of Science ®Google Scholar
• Ortego-Centeno N, Munoz-Torres M, Jodar E, Hernandez-Quero J, Jurado-Duce A, De La Higuera Torres-Puchol J. Effect of tobacco consumption on bone mineral density in healthy young males. Calcif Tissue Int. 1997;60(6):496–500.9164822
   PubMed Web of Science ®Google Scholar
• Inoue D, Watanabe R, Copd OR. and osteoporosis: links, risks, and treatment challenges. Int J Chron Obstruct Pulmon Dis. 2016;11:637–648. doi:10.2147/COPD.S7963827099481
   PubMed Web of Science ®Google Scholar
• Aung K, Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev. 2011;5(10):CD005185.
   Google Scholar
• Berg KM, Kunins HV, Jackson JL, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med. 2008;121(5):406–418. doi:10.1016/j.amjmed.2007.12.01218456037
   PubMed Web of Science ®Google Scholar
• Byreddy DV, Bouchonville MF 2nd, Lewiecki EM. Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors. Climacteric. 2015;18(Suppl 2):39–46. doi:10.3109/13697137.2015.110361526488130
   PubMed Web of Science ®Google Scholar
• Drake MT, Murad MH, Mauck KF, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1861–1870. doi:10.1210/jc.2011-305822466344
   PubMed Web of Science ®Google Scholar
• Guo M, Qu H, Xu L, Shi DZ. Tea consumption may decrease the risk of osteoporosis: an updated meta-analysis of observational studies. Nutr Res. 2017;42:1–10. doi:10.1016/j.nutres.2017.02.01028633866
   PubMed Web of Science ®Google Scholar
• Liu J, Zhu LP, Yang XL, Huang HL, Ye DQ. HMG-CoA reductase inhibitors (statins) and bone mineral density: a meta-analysis. Bone. 2013;54(1):151–156. doi:10.1016/j.bone.2013.01.04423388418
   PubMed Web of Science ®Google Scholar
• Moayeri A, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag. 2017;13:455–468. doi:10.2147/TCRM.S13194528442913
   PubMed Web of Science ®Google Scholar
• Watts NB. Adverse bone effects of medications used to treat non-skeletal disorders. Osteoporos Int. 2017;28(10):2741–2746. doi:10.1007/s00198-016-3774-528752332
   PubMed Web of Science ®Google Scholar
• Zhang ZF, Yang JL, Jiang HC, Lai Z, Wu F, Liu ZX. Updated association of tea consumption and bone mineral density: A meta-analysis. Medicine (Baltimore). 2017;96(12):e6437. doi:10.1097/MD.000000000000643728328853
   PubMed Web of Science ®Google Scholar